FindTrial
Sign In

DRP-104

DRUG4 trials

Sponsors

Dracen Pharmaceuticals, Inc., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, NYU Langone Health

Conditions

Advanced Solid TumorFibrolamellar Hepatocellular CarcinomaLiver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))Non Small Cell Lung CancerNon Small Cell Lung Cancer Metastatic

Phase 1

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors
TerminatedNCT04471415
Dracen Pharmaceuticals, Inc.Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic
Start: 2020-08-31End: 2023-03-28Updated: 2023-06-12
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
RecruitingNCT06027086
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsFibrolamellar Hepatocellular Carcinoma
Start: 2024-02-12End: 2033-09-01Target: 27Updated: 2026-02-12
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Not yet recruitingNCT07430202
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLiver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Start: 2026-09-01End: 2030-09-01Target: 27Updated: 2026-08-25

Phase 2

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
RecruitingNCT07249372
NYU Langone HealthNon Small Cell Lung Cancer
Start: 2026-01-14End: 2028-10-31Target: 37Updated: 2026-05-26

Related Papers

Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD(L)1 therapy.
Journal of Clinical Oncology2024-01-205 citations
Abstract 4904: Glutamine antagonist DRP-104 enhances anti-tumor responses in <i>KEAP1</i> mutant lung cancer
Cancer Research2023-04-04
Abstract 3027: Elucidating the role of glutamine metabolism in head &amp; neck squamous cell carcinoma
Cancer Research2022-06-15
Abstract 2174: Sirpiglenastat (DRP-104), a novel broad acting glutamine antagonist, has therapeutic potential in targeting KEAP1-mutant lung cancer
Cancer Research2022-06-15
Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.
Journal of Clinical Oncology2021-05-2019 citations